Tue, 02nd Jun 2015 14:59
** Juno Therapeutics up more than 13 pct onreported AstraZeneca interest in immuno-oncology sector
** Traders cite Astra CEO saying in interview to Bloombergthat saying companies like Juno could be of potential interest
** Bounce in Juno shares lifts peers Bellicum Pharma, up 5.2 pct, and Affimed, up 4.4 pct
** CEO adds in interview that potential CAR-T cell therapiesmust be able to manage side effects before any Astra purchase
(RM: vikram.subhedar.thomsonreuters.com@reuters.net)
(Correcting company name in headline)
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...
(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...
Astrazeneca (AZN)